- A	- Tal - 1	
Please type a plus sign (+	) inside x	

04-04-21

A PTO/S

PTO/SB/05 (08-00)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## UTILITY PATENT APPLICATION TRANSMITTAL

Attorne	y Docket No.	LEX-0160-USA
First Inventor Yi Hu et al.		
Title Novel Human Ion Channel Protein and Polynucleotides Encoding the Same		
Expres	s Mail label No.	

(Only for new nonprovisional applications under 37 CFR 1.53 (b))

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231		
Fee Transmittal Form (e.g., PTO/SB/17)     (Submit an original and a duplicate for fee processing)	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)		
2. Applicant claims small entity status. See 37 CFR 1.27.	8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)		
3. X Specification [Total Pages (preferred arrangement set forth below) 29	a. Computer Readable Form (CRF)		
Descriptive title of the Invention     Cross Reference to Related Applications	b. Specification Sequence Listing on:		
- Statement Regarding Fed sponsored R & D	i. CD-ROM or CD-R (2 copies); or		
<ul> <li>Reference to sequence listing, a table, or a computer program listing appendix</li> </ul>	i.i. 🗵 paper		
Background of the Invention     Brief Summary of the Invention	c. Statements verifying identity of above copies		
- Brief Description of the drawings (if filed)	ACCOMPANYING APPLICATION PARTS		
- Detailed Description - Claim(s)	Assignment Papers (cover sheet & document(s))		
- Abstract of the disclosure	37 CFR 3.73(b) Statement X Power of Attorney		
4. Drawing(s)(35 U.S.C.113) [Total Sheets ]	11. English Translation Document (if applicable)		
5. Oath or Declaration [Total Pages 2]	12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations		
a. X Unexecuted (original or copy)	13. Preliminary Amendment		
b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed)	14. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized)		
i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s)	15. Certified Copy of Priority Document(s) (if foreign priority is claimed)		
named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	16. Other:		
6. Application Data Sheet. See 37 CFR 1.76			
17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:			
Continuation Divisional Continuation-in-part (CIP) of prior application No.:			
Prior application information: Examiner Group/Art Unit:  For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under			
l manufication and is neglected at the displacation of the ecomposition continuation or divisional application and is neglect incorporated by reference.			
The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.  18. COLINE CE ADDRESS			
Customer Number or Bar Code Label	or Correspondence address below		
Name PATENT TRADEN	MARK OFFICE		
Address			
City State	Zip Code		
Country Telephone	Fax 1		
	Lance K tenimoto Registration No. (Attorney/Agent) 41866		
Signature	Date April 3, 2001		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.